With this funding, FAU researchers will shed light on the biological functions of Alzheimer’s disease (AD) by taking advantage of synthetic chemistry strategies; provide an innovative online screening tool for older drivers with cognitive decline; and gain a deeper understanding of the role of brain cholesterol in AD.
NeuroTherapia, an early-stage clinical pharmaceutical company, announced today that it has received a grant from the Alzheimer's Association Part the Cloud program for the development of its first-in-class drug, NTRX-07, for the treatment of Alzheimer's disease (AD).
UCLA Health researchers have discovered a mechanism that creates memories while reducing metabolic cost, even during sleep. This efficient memory occurs in a part of the brain that is crucial for learning and memory, and where Alzheimer’s disease begins.
Laurence Belfer, on behalf of Robert Belfer and the Belfer family, today announced a $20 million gift to The University of Texas MD Anderson Cancer Center to strengthen neurodegeneration research through the Belfer Neurodegeneration Consortium (BNDC), a transformative multi-institutional initiative to advance the study and treatment of Alzheimer’s disease.
“AI-driven neuroimaging techniques have the potential to improve prediction models for Alzheimer’s progression and facilitate personalized treatment strategies,” says Domenico Praticò, MD, the Scott Richards North Star Foundation Chair for Alzheimer’s Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer’s Center at Temple (ACT), at the Lewis Katz School of Medicine at Temple University (LKSOM).
By transplanting human neural stem cells, researchers improved memory and reduced neuroinflammation in a mouse model of Alzheimer’s Disease, suggesting another avenue for potential treatment, a study shows. Researchers say the improvements reported after stem cell transplantation must be further studied in mice before advancing to larger animals and, eventually, humans.
A newly developed nanomaterial that mimics the behavior of proteins could be an effective tool for treating Alzheimer’s and other neurodegenerative diseases. The nanomaterial alters the interaction between two key proteins in brain cells — with a potentially powerful therapeutic effect.
Alzheimer’s treatment studies offer hope as UNLV expert predicts new potential drugs, biomarkers will yield critical insight for future development.
Patients with a common movement disorder known as essential tremor (ET) developed dementia at three times the rate of similarly aged people in the general population, a study led by UT Southwestern Medical Center researchers shows. Their findings, published in the Annals of Neurology, provide the first concrete data to help doctors counsel those with this condition on their cognitive prognosis, future plans, and potential treatments, the authors said.
The gathering brings together industry experts and leading researchers to bring the latest science to the people in an interactive forum where they can exchange current information and ongoing advances.
Using state-of-the-art microscopy techniques developed on campus, researchers at UC San Diego School of Medicine have shed new light on the underlying mechanisms driving Alzheimer’s disease.
An intricate simulation performed by UT Southwestern Medical Center researchers using one of the world’s most powerful supercomputers sheds new light on how proteins called SNAREs cause biological membranes to fuse.
The harder your brain works at your job, the less likely you may be to have memory and thinking problems later in life, according to a new study published in the April 17, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
“Are the risk factors for early onset Alzheimer’s the same as late onset?” asks Domenico Praticò, MD, the Scott Richards North Star Foundation Chair for Alzheimer’s Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer’s Center at Temple (ACT), at the Lewis Katz School of Medicine at Temple University (LKSOM)
Caring for someone with dementia or Alzheimer’s disease is challenging. In addition to the financial and physical demands, many caregivers are unprepared for the stress of trying to effectively communicate with a loved one who may be prone to agitation, verbal aggression, and hallucinations.
A changing climate may be linked to growing death and disability from stroke in regions around the world, according to a study published in the April 10, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Racial discrimination experienced during midlife is associated with Alzheimer’s disease pathology, according to a new study from researchers at Wake Forest University School of Medicine and the University of Georgia. The findings appear online today in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
In findings published in Cell Reports, senior author Jerold Chun, M.D., Ph.D., and team also discovered that the biological instructions within these vesicles differed significantly in postmortem brain samples donated from patients suffering from Alzheimer’s disease.
Proteins known as oligomeric chaperones help suppress the formation of misshaped proteins that cause a variety of degenerative and neurodegenerative diseases, such as Alzheimer’s, Huntington’s, and Parkinson’s. In a new study, UT Southwestern Medical Center researchers identified a key feature necessary for one of these oligomeric chaperones, known as DNAJB8, to assemble from disparate parts and showed that the parts alone can reshape misfolded proteins. The findings, published in Structure, could lead to better ways to diagnose and treat these conditions.
Researchers from the Perelman School of Medicine at the University of Pennsylvania will present data on the latest research across the full spectrum of Neurology – including a link between head injury and suicide, potential traumatic brain injury biomarkers, a promising new drug to treat multiple sclerosis – at the American Academy of Neurology (AAN) Annual Meeting from April 13-18 in Denver, Colorado. Follow us on Twitter @PennMedicine and @PennMDForum for updates.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right